Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma

NCT00002556 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00002556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
July 31, 1994
Completion date
Not reported
Enrollment
312 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage i multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma